A Large-scale Digital Survey of Patients with Localized and Advanced Prostate Cancer in Germany, the UK, and the USA
This study highlights differences in the PC patient journey in Germany, the UK, and the USA. HRQoL did not differ between countries but was affected by advanced disease status and comorbidity burden. A common approach to PC diagnosis, treatment practices, and guidelines could improve outcomes.
Authors
- Howard Wolinsky (ORCID: https://orcid.org/0000-0003-4426-6735)
- R. Lehmann
- Brian D. Gonzalez (ORCID: https://orcid.org/0000-0001-5108-5735)
- Osvaldo Mirante
- Axel Heidenreich (ORCID: https://orcid.org/0000-0002-2511-3664)
- Joe M. O’Sullivan (ORCID: https://orcid.org/0000-0001-6999-2739)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Lisa M. Gudenkauf (ORCID: https://orcid.org/0000-0001-6825-5921)
- Andreas Poschenrieder (ORCID: https://orcid.org/0000-0002-2813-7354)
- Stephen Allen (ORCID: https://orcid.org/0000-0001-6675-249X)
- Carl Ernst-Gunther
Institutions
- Queen's University Belfast (GB)
- Fluor (United States) (US)
- Novartis (Switzerland) (CH)
- Moffitt Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Prostate Cancer UK (GB)
- Medical University of Vienna (AT)
- Donbas National Academy of Civil Engineering and Architecture (UA)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.euo.2025.03.006
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00